Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Current Assets (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Current Assets readings, the most recent being $19.0 million for Q4 2017.

  • On a quarterly basis, Current Assets rose 1552.17% to $19.0 million in Q4 2017 year-over-year; TTM through Dec 2017 was $19.0 million, a 1552.17% increase, with the full-year FY2017 number at $19.0 million, up 1552.17% from a year prior.
  • Current Assets hit $19.0 million in Q4 2017 for Eledon Pharmaceuticals, down from $21.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $107.5 million in Q4 2014 to a low of $1.2 million in Q4 2016.
  • Median Current Assets over the past 5 years was $46.2 million (2016), compared with a mean of $53.6 million.
  • Biggest five-year swings in Current Assets: plummeted 98.29% in 2016 and later skyrocketed 1552.17% in 2017.
  • Eledon Pharmaceuticals' Current Assets stood at $32.2 million in 2013, then soared by 234.11% to $107.5 million in 2014, then crashed by 37.52% to $67.2 million in 2015, then plummeted by 98.29% to $1.2 million in 2016, then skyrocketed by 1552.17% to $19.0 million in 2017.
  • The last three reported values for Current Assets were $19.0 million (Q4 2017), $21.0 million (Q3 2017), and $24.8 million (Q2 2017) per Business Quant data.